Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US OTC Monograph Reform's Early Results Could Be Label Orders From FDA, Wait And See For Industry

Apr 16 2020

• By Malcolm Spicer

Stop Wait Go Glossy Button, Vector illustration

Related Content

'Real Challenge' To Improve OTC Monograph Program Without User Fees – FDA

Jun 16 2016

US Pandemic Relief Package Delivers OTC Industry Regulatory Wishes, Supplement Business Hopes

Mar 27 2020

Exclusivity Period Allowed By OTC Monograph Reform Likely Up To Conference Committee

Jul 19 2018

Monograph Reform Legislation In Play As FDA, OTC Industry Get Real On Changes

May 23 2019

Never Mind Next-Gen UV Filters; Existing Sunscreen Ingredients’ GRASE Status May Be In Danger

Feb 11 2019

Additional Topics

International United States OTC Drugs Legislation Drug Approval Standards Advertising, Marketing & Sales Business Strategies Commercial Compliance FDA Ingredients Manufacturing Policy Regulation Consumer

More from International

More from Geography

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.